Steve Jackson

Steve Jackson is a founding figure in DNA damage response research whose laboratory identified and characterized ATM, DNA-PK, and PARP as central regulators of the cellular response to DNA double-strand breaks. His mechanistic discoveries of how cells sense and respond to DNA damage laid the scientific foundation for the clinical development of PARP inhibitors as cancer therapeutics. He co-founded Kudos Pharmaceuticals, which developed olaparib, the first approved PARP inhibitor. His FRS-honored career spans biochemical mechanisms of NHEJ, the DNA damage checkpoint, and DDR-targeted therapy.